ECM
TEVA icon

ETrade Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

ETrade Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,410
Closed -$163K – 830
2019
Q1 		$163K Buy
+10,410
New +$184K ﹤0.01% 785
2018
Q4 		– Sell
-9,999
Closed -$215K – 820
2018
Q3 		$215K Sell
9,999
-674
-6% -$15.6K 0.01% 776
2018
Q2 		$260K Sell
10,673
-336
-3% -$6.85K 0.01% 689
2018
Q1 		$188K Buy
+11,009
New +$215K 0.01% 729
2017
Q4 		– Sell
-13,147
Closed -$231K – 766
2017
Q3 		$231K Sell
13,147
-3,803
-22% -$85.6K 0.01% 644
2017
Q2 		$563K Sell
16,950
-643
-4% -$19.9K 0.02% 434
2017
Q1 		$565K Sell
17,593
-10,529
-37% -$359K 0.02% 410
2016
Q4 		$1.02M Sell
28,122
-8,087
-22% -$323K 0.05% 231
2016
Q3 		$1.67M Buy
36,209
+1,894
+6% +$98.8K 0.08% 152
2016
Q2 		$1.72M Buy
34,315
+12,402
+57% +$660K 0.09% 136
2016
Q1 		$1.17M Buy
21,913
+691
+3% +$40.5K 0.07% 171
2015
Q4 		$1.39M Sell
21,222
-514
-2% -$31.8K 0.08% 141
2015
Q3 		$1.23M Sell
21,736
-756
-3% -$49K 0.08% 158
2015
Q2 		$1.33M Buy
22,492
+960
+4% +$59.2K 0.08% 161
2015
Q1 		$1.34M Buy
21,532
+4,546
+27% +$264K 0.08% 163
2014
Q4 		$977K Buy
16,986
+2,668
+19% +$149K 0.06% 200
2014
Q3 		$770K Buy
14,318
+3,733
+35% +$198K 0.05% 224
2014
Q2 		$555K Buy
10,585
+4,998
+89% +$255K 0.04% 247
2014
Q1 		$295K Buy
5,587
+2,909
+109% +$134K 0.02% 273
2013
Q4 		$107K Buy
2,678
+1,192
+80% +$46.9K 0.01% 353
2013
Q3 		$56K Buy
1,486
+785
+112% +$30.6K 0.01% 413
2013
Q2 		$27K Buy
+701
New +$27.3K ﹤0.01% 457

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ETrade Capital Management's TEVA Position: Q2 2019 in Review

ETrade Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 10,410 shares — an estimated $163K sold.

ETrade Capital Management first reported a position in TEVA in Q2 2013 and held it in 22 quarters. The position peaked at $1.72M in Q2 2016. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • ETrade Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • ETrade Capital Management sold 10,410 Teva Pharmaceuticals shares in Q2 2019, an estimated $163K.
  • ETrade Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • ETrade Capital Management's Teva Pharmaceuticals position peaked at $1.72M in Q2 2016.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on ETrade Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.